NCT04418427 - ADVM-022 Intravitreal Gene Therapy for DME | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 28, 2020

Primary Completion Date

November 22, 2022

Study Completion Date

June 14, 2023

Conditions

Diabetic Macular EdemaDiabetic Retinopathy

Interventions

BIOLOGICAL

6E11 vg/eye of ADVM-022

ADVM-022 (AAV.7m8-aflibercept) is a recombinant, replication-incompetent adeno-associated virus (AAV.7m8) gene therapy vector carrying a coding sequence for aflibercept

BIOLOGICAL

2E11 vg/eye of ADVM-022

ADVM-022 (AAV.7m8-aflibercept) is a recombinant, replication-incompetent adeno-associated virus (AAV.7m8) gene therapy vector carrying a coding sequence for aflibercept

BIOLOGICAL

Aflibercept

Commercially available Active Comparator

Trial Locations (14)

19107

Adverum Clinical Site, Philadelphia

29169

Adverum Clinical Site, West Columbia

33064

Adverum Clinical Site, Deerfield Beach

37203

Adverum Clinical Site, Nashville

77030

Adverum Clinical Site, Houston

77384

Adverum Clinical Site, The Woodlands

78705

Adverum Clinical Site, Austin

79606

Adverum Clinical Site, Abilene

80401

Adverum Clinical Site, Golden

85014

Adverum Clinical Site, Phoenix

89502

Adverum Clinical Site, Reno

90211

Adverum Clinical Site, Beverly Hills

93309

Adverum Clinical Site, Bakersfield

00612

Adverum Clinical Site, Arecibo